DOES YOUR BABY HAVE INFANTILE HEMANGIOMA?

Your baby may qualify for a RESEARCH STUDY to evaluate the safety and
effectiveness of two treatments that may prevent growth of hemangiomas –
pulsed-dye laser treatment, and timolol maleate 0.5% opthalmic solution
topical treatment for very early infantile hemangiomas. Pulsed-dye laser is
widely used in children, and is approved by the FDA for treating
hemangioma. This procedure has a few minor side effects that are most
often temporary. Timolol is used frequently for the treatment of childhood
glaucoma with few side effects, and has been shown to be effective in
treating a case of hemangioma in infant. It is not yet an approved treatment
for hemangioma. An important question being tested in this study is
whether these treatments can prevent hemangioma from growing, when
used very early after the birth of your child.

- Your infant is less than 3 months, male or female.
- Your infant has one or more superficial hemangiomas in the very early stage
- Your infant has no severe heart, asthma or lung disease
- Your infant is not on any other treatment for the hemangioma
- Photos, measurements, and treatment with either pulsed-dye laser or timolol or no treatment
- Up to 13 study visits, less than 1 hour each, over two years period
- Up to $385 in compensation for time and travel (parking sticker will also be provided)

More information can be found at:
http://www2.massgeneral.org/wellman/

Institution  –  MGH - Massachusetts General Hospital, Boston, MA; BWH - Brigham and Women's Hospital, Boston, MA; NWH, Newton, MA; North Shore Medical Center, Salem, MA; Beth Israel Deaconess, Boston, MA; Boston University Medical Center, Boston, MA; MIT, Cambridge, MA; Massachusetts General Hospital - East, Charlestown, MA

Principal Investigator  – Richard R Anderson, MD

  

For further information about enrolling a patient in this trial, contact the person below.

Name  – Ray H Jalian, MD

Phone  – 617-724-4937